BioCardia announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
- BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
- Is BCDA a Buy, Before Earnings?
- BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
- BioCardia, StemCardia enter biotherapeutic delivery partnership
